RxDoctor Payments Data

Brian Baesler, MD

Family Medicine · Franklin, LANPI 1184980799

Payments from drug & device makers

$538in general payments, 2019–2025

Across 27 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$230
  • Axsome Therapeutics, Inc.$57
  • Lilly USA, LLC$56
  • Boehringer Ingelheim$32
  • Lundbeck LLC$32
  • AstraZeneca$31
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$538100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$538 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$30,154
Medicare patients
91
Services billed
363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$154,605
TrulicityDulaglutide57$56,509
MounjaroTirzepatide31$38,547
JardianceEmpagliflozin48$33,835
EliquisApixaban34$24,602
JanuviaSitagliptin Phosphate31$22,511
LinzessLinaclotide36$19,429
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$19,019
FarxigaDapagliflozin Propanediol26$14,813
JanumetSitagliptin Phos/Metformin Hcl16$13,389
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$8,720
SymbicortBudesonide/Formoterol Fumarate24$6,466
XareltoRivaroxaban12$6,446
Combivent RespimatIpratropium/Albuterol Sulfate11$5,512
MyrbetriqMirabegron11$5,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$154,605154 claims
Lilly USA, LLCTrulicity, Mounjaro$56$95,05588 claims
Boehringer IngelheimJardiance, Combivent Respimat$32$39,34859 claims
AstraZenecaFarxiga, Symbicort$31$21,27950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Franklin

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →